TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03994744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of Sintilimab (1200mg/3weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.
Study: NCT01180790

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
Study: NCT02707588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
Study: NCT02635542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
Study: NCT04854850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo
Description: The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
Study: NCT02635542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
Study: NCT02660879

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written Document Educational Resource
Description: A 2 page document with pictures discussing how to use an inhaler properly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Video Education
Description: Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
Study: NCT02394236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
Study: NCT03724266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: chitosan will be used as intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: intracanal medication
Study: NCT01980810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bounded paclitaxel
Description: 200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
Study: NCT01180790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
Study: NCT02450552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine
Description: Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine
Description: Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00937248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prone pillow and simple ankle fixation device
Description: Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized Vacuum Immobilization Device (CVID)
Description: This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
Study: NCT05020405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and ARS with GBR and SMV
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement and ARS with GBR
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
Study: NCT01267084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or equivalent steroid
Description: Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or equivalent steroid
Description: Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
Study: NCT01931241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHRO-001
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
Study: NCT00347594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Diagnostic Instrument (NGDI)
Description: Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zyoptix Diagnostic Workstation (ZDW)
Description: Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
Study: NCT04842591

Intervention type: DIAGNOSTIC_TEST
Intervention: exercise echocardiography
Description: All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
Study: NCT02769039

Intervention type: OTHER
Intervention: No intervention. Observational studies of sleep, movement and brain imaging
Description: Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.

Intervention type: OTHER
Intervention: No intervention. Observational studies of sleep, movement and brain imaging
Description: Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
Study: NCT00634049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
Study: NCT01232621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Introduction of research personnel
Description: Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Introduction of research personnel
Description: Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
Study: NCT04679051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration
Description: Participants will be asked to alter time in bed to achieve specified sleep durations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration
Description: Participants will be asked to alter time in bed to achieve specified sleep durations.
Study: NCT04288817

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tuberculin purified protein derivative
Description: Intralesional injection of tuberculin PPD in treatment of multiple common warts
Study: NCT00864838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg 1 hour before intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartarate
Description: 1 drop 1 hour before intravitreal injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis
Description: Immediately after bevacizumab injection
Study: NCT01339988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan/Cyclophosphamide
Description: Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days.
Study: NCT03706157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Study: NCT04399187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium hypochlorite gel application
Description: Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel application
Description: Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
Study: NCT04448236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction resistance exercise
Description: Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension
Study: NCT01402167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Description: Patients will be treated via a balloon kyphoplasty surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Patients will be treated via a transcutaneous vertebroplasty procedure.
Study: NCT04545294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta tACS
Description: See detail in arm/group descriptions regarding the intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta tACS
Description: See detail in arm/group descriptions regarding the intervention.
Study: NCT01666054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV
Description: Pressure Support Ventilation will be used until patient is extubated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAV
Description: Proportional Assist Ventilation will be used until patient is extubated.
Study: NCT00744237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER
Description: * Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: * HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
Study: NCT02240589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
Study: NCT00030368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04020003

Intervention type: DRUG
Group type: OTHER
Intervention: Levosimendan
Description: General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
Study: NCT03481790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: (Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferrous sulphate + folic acid (vitamin B9)
Description: (Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
Study: NCT03004664

Intervention type: BEHAVIORAL
Intervention: Support Empowerment Model
Description: The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.

Intervention type: BEHAVIORAL
Intervention: The Chronic Care Model
Description: the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
Study: NCT04161417

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Description: Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
Study: NCT02492646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline group
Description: After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry group
Description: After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
Study: NCT01649596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warming Gown
Description: Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care warming
Description: The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
Study: NCT00164853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic balloon dilatation
Description: Refer to description under arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sphincterotomy
Description: Refer to under arms
Study: NCT00720408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf-XL
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: oral